Drugs / CD19 Chimeric Antigen Receptor (CAR) T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04943016 | Jul 2021 → Dec 2024 | B-cell neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 Chimeric Antigen Receptor (CAR) T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943016 ↗ |
| Modality | Cell therapy | “autologous T cells that have been modified through the introduction of a chimeric antigen receptor” NCT04943016 ↗ |
| Target | CD19 | “targeting the B cell surface antigen CD19” NCT04943016 ↗ |